Sichenzia Ross Ference LLP Represents Boustead Securities, LLC as Underwriter to MAINZ BIOMED B.V. in $11.5 Million U.S. Initial Public Offering

Press Release – New York, NY – November 11, 2021 – Sichenzia Ross Ference LLP congratulates MAINZ BIOMED B.V. (the “Company”) (NASDAQ: MYNZ ), a molecular genetics diagnostic company specializing in the early detection of cancer, on the final closing of its initial public offering on November 9, 2021. The Company raised $11.5 million in gross proceeds, before deducting underwriting discounts, commissions and other offering expenses, by issuing 2,300,000 common shares at a public offering price of $5.00 per share. The ordinary shares commenced trading on the Nasdaq Capital Market on November 5, 2021 under the ticker symbol “MYNZ”.
Boustead Securities, LLC acted as the sole underwriter for the offering and the Firm acted as legal counsel to the underwriter. The Sichenzia Ross Ference LLP team was led by Senior Partner, Benjamin Tan.
- Sichenzia Ross Ference LLP Represents Verb Technology Company, Inc. in $7.2 Million Underwritten Public Offering of Common Stock - January 26, 2023
- Sichenzia Ross Ference LLP Represents Jupiter Wellness, Inc. in $4.1 Million Registered Direct Offering and Concurrent Private Placement of Warrants - January 24, 2023
- Sichenzia Ross Ference LLP Represents Network 1 Financial Securities, Inc. in $69 Million Public Offering of Horizon Space Acquisition I Corp. - January 9, 2023